Search

Your search keyword '"Satake H"' showing total 885 results
Start Over Author "Satake H"
885 results on '"Satake H"'

52. Primary results of multicenter phase II study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PII)

Author

Miki, A., primary, Satake, H., additional, Watanabe, T., additional, Tanaka, N., additional, Hirata, K., additional, Shimozaki, K., additional, Tanioka, H., additional, Matsuura, M., additional, Kyogoku, T., additional, Tatsumi, M., additional, Matoba, K., additional, Oka, Y., additional, Adachi, S., additional, Yasui, H., additional, Kotaka, M., additional, Kato, T., additional, and Tsuji, A., additional

Published
2019
Full Text
View/download PDF

53. SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer

Author

Munemoto, Y., primary, Nakamura, M., additional, Takahashi, M., additional, Kotaka, M., additional, Kuroda, H., additional, Kato, T., additional, Minagawa, N., additional, Noura, S., additional, Fukunaga, M., additional, Kuramochi, H., additional, Touyama, T., additional, Takahashi, T., additional, Miwa, K., additional, Satake, H., additional, Kurosawa, S., additional, Miura, T., additional, Mishima, H., additional, Sakamoto, J., additional, Oba, K., additional, and Nagata, N., additional

Published
2019
Full Text
View/download PDF

54. Relationship between peripheral neuropathy and effectiveness in second-line chemotherapy for unresectable advanced gastric cancer: a prospective, observational, multicenter study protocol

Author

Tanioka, H., primary, Nagasaka, T., additional, Uno, F., additional, Inoue, M., additional, Okita, H., additional, Katata, Y., additional, Kanzaki, H., additional, Kuramochi, H., additional, Satake, H., additional, Shindo, Y., additional, Doi, A., additional, Nasu, J., additional, Yamashita, H., additional, and Yamaguchi, Y., additional

Published
2019
Full Text
View/download PDF

55. RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC)

Author

Sunakawa, Y., primary, Nakamura, M., additional, Ishizaki, M., additional, Kataoka, M., additional, Satake, H., additional, Kitazono, M., additional, Yanagisawa, H., additional, Kawamoto, Y., additional, Kuramochi, H., additional, Ohori, H., additional, Takahashi, K., additional, Maeda, F., additional, Komeno, C., additional, Takeuchi, M., additional, Fujii, M., additional, Yoshino, T., additional, Ichikawa, W., additional, and Tsuji, A., additional

Published
2019
Full Text
View/download PDF

57. Antigraviceptive neck muscle responses to 'moving up and moving down' in human

Author

Aoki, M, Han, X. Y, Yamada, H, Muto, T, Satake, H, Ito, Y, and Matsunami, K

Subjects
Life Sciences (General)
Abstract

The responses of neck muscle to sudden transit from one 'g' to hyper 'g', work to support the head and remain the relative position of head on trunk as common observed: i.e. in sudden acceleration or deceleration by car or ejection of pilot from aircraft. Accordingly it is highly possible that the neck muscle responses to moving up may be important to prevent the neck injury due to sudden linear acceleration such as moving up against gravity. However little is known about the evaluation of mechanism of this reflex. Therefore the present study was conducted with two aims. The first aim was to investigate the neck muscle responses to vertical linear acceleration bv 0.4 g produced with an electro-hydraulic servo-system. We chose the vertical linear acceleration because it activates mainly sacculus, from which afferents have been demonstrated to be connected directly to sternocleidomastoid muscle in animals and human. The second aim was to determine whether there is a difference of neck muscle response to moving down and moving up.

Published
2000

60. The Effect of Chitosan and Chitin Oligomers on Gene Expression and Lignans Production in Linum album Cell Cultures

Author

Esmaeilzadeh Bahabadi, S., Sharifi, M., Jun Murata, and Satake, H.

Subjects
carbohydrates (lipids), linum album, RA1190-1270, Toxicology. Poisons, gene expression, macromolecular substances, podophyllotoxin, Therapeutics. Pharmacology, RM1-950, chitosan oligomers
Abstract

Background: Linum album, a herbaceous and medicinal plant, has been shown to accumulate anti-tumor podophyllotoxin (PTOX) and related lignans. Objective: In this study, we have verified the time-course of cell growth, lignan production in cells treated with chitosan and chitin oligomers. To study mechanism of chitosan and chitin oligomers action, expression of phenylalanine ammonio-lyase (PAL), cinnamoyl-CoA reductase (CCR), cinnamyl alcohol dehydrogenase (CAD) and pinoresinol lariciresinol reductase (PLR) genes were investigated. Methods: The cells were treated with 100 mg l-1 chitin and chitosan oligomers. Cells were harvested for 5 days after elicitation. lignans quantified by reverse-phase high-performance liquid chromatography (HPLC). Cell samples frozen with liquid N2 were used to elucidate the expression level of genes by quantitative PCR (qPCR). Results: Cells elicited with chitosan hexamer for 5 days yielded the highest amount of PTOX (73.5 µg/g dry weight) and lariciresinol (96 µg/g DW) which were about 3-fold and 2-fold higher than control, respectively. The expression of genes by oligomers was increased, reaching a peak at 3 day after treatment. Conclusion: Chitosan and chitin oligomers up-regulate the production of PTOX, by effecting on gene expression of PTOX biosynthesis pathway.

Published
2014

62. Phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): Phase Ib results

Author

Kagawa, Y., primary, Satake, H., additional, Kato, T., additional, Oba, K., additional, Yasui, H., additional, Nakamura, M., additional, Watanabe, T., additional, Hirata, K., additional, Muro, K., additional, Komatsu, Y., additional, Yoshino, T., additional, Yamazaki, K., additional, Mishima, H., additional, Kotaka, M., additional, Tsuji, A., additional, Kakeji, Y., additional, Oki, E., additional, Nagata, N., additional, and Junichi, S., additional

Published
2018
Full Text
View/download PDF

64. Efficacy and safety of a recombinant soluble human thrombomodulin (ART-123) in preventing oxaliplatin induced peripheral neuropathy (OIPN): Results of a placebo-controlled, randomized, double-blind phase II study

Author

Kato, T., primary, Kotaka, M., additional, Satake, H., additional, Makiyama, A., additional, Tsuji, Y., additional, Shinozaki, K., additional, Fujiwara, T., additional, Mizushima, T., additional, Harihara, Y., additional, Nagata, N., additional, Kurihara, N., additional, Kagawa, Y., additional, Kusakawa, G., additional, Sakai, T., additional, Uchida, Y., additional, Takamoto, M., additional, Asami, S., additional, Ando, M., additional, Saito, Y., additional, and Hyodo, I., additional

Published
2018
Full Text
View/download PDF

65. Prospective evaluation of regorafenib dose escalation strategy with low starting dose in patients with colorectal cancer

Author

Masuishi, T., primary, Suzuki, T., additional, Sukawa, Y., additional, Imamura, C.K., additional, Satake, H., additional, Kumekawa, Y., additional, Funakoshi, S., additional, Kotaka, M., additional, Horie, Y., additional, Kawai, S., additional, Okuda, H., additional, Terazawa, T., additional, Kondoh, C., additional, Kato, K., additional, Yoshimura, K., additional, Ishikawa, H., additional, Hamamoto, Y., additional, Boku, N., additional, Kanai, T., additional, and Takaishi, H., additional

Published
2018
Full Text
View/download PDF

66. Phase II study of S-1 and oxaliplatin as neo-adjuvant chemotherapy for locally advanced gastric and esophago-gastric cancer (KSCC1601)

Author

Kobayashi, K., primary, Iwatsuki, M., additional, Orita, H., additional, Hidaka, S., additional, Arigami, T., additional, Kusumoto, T., additional, Satake, H., additional, Oki, E., additional, Satoshi, K., additional, Tobimatsu, K., additional, Shimokawa, M., additional, Saeki, H., additional, Makiyama, A., additional, Kakeji, Y., additional, Natsugoe, S., additional, Baba, H., additional, Eguchi, S., additional, and Maehara, Y., additional

Published
2018
Full Text
View/download PDF

67. Phase II study of cetuximab rechallenge in patients with ras wild-type metastatic colorectal cancer: E-rechallenge trial

Author

Osawa, H., primary, Shinozaki, E., additional, Nakamura, M., additional, Ohhara, Y., additional, Shindo, Y., additional, Shiozawa, M., additional, Uetake, H., additional, Matsumoto, H., additional, Ureshino, N., additional, Satake, H., additional, Kobayashi, T., additional, Suto, T., additional, Kitano, S., additional, Ohashi, Y., additional, Uemura, K., additional, and Yamaguchi, K., additional

Published
2018
Full Text
View/download PDF

68. Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B

Author

Yuki, S., primary, Shinozaki, K., additional, Kashiwada, T., additional, Kusumoto, T., additional, Iwatsuki, M., additional, Satake, H., additional, Tokunaga, S., additional, Emi, Y., additional, Makiyama, A., additional, Kawamoto, Y., additional, Komatsu, Y., additional, Shimokawa, M., additional, Saeki, H., additional, Oki, E., additional, Baba, H., additional, and Maehara, Y., additional

Published
2018
Full Text
View/download PDF

69. Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)

Author

Takahashi, H., primary, Morizane, C., additional, Nomura, S., additional, Okano, N., additional, Tsuda, M., additional, Mizuno, N., additional, Satake, H., additional, Tsuji, K., additional, Shioji, K., additional, Ishii, H., additional, Yasui, K., additional, Miyakawa, H., additional, Ishiguro, A., additional, Ogura, T., additional, Ueno, M., additional, Ikeda, A., additional, Terashima, T., additional, Ikeda, M., additional, Okusaka, T., additional, and Furuse, J., additional

Published
2018
Full Text
View/download PDF

70. A randomized phase II trial of adjuvant chemotherapy with gemcitabine versus S-1 after major hepatectomy for biliary tract cancer: Kansai Hepato-Biliary Oncology Group (KHBO1208)

Author

Terajima, H., primary, Kobayashi, S., additional, Nagano, H., additional, Tomokuni, A., additional, Gotoh, K., additional, Sakai, D., additional, Hatano, E., additional, Seo, S., additional, Uchida, Y., additional, Ajiki, T., additional, Satake, H., additional, Kamei, K., additional, Tohyama, T., additional, Hirose, T., additional, Ikai, I., additional, Morita, S., additional, and Ioka, T., additional

Published
2018
Full Text
View/download PDF

71. Gene mutation status in circulating tumor DNA (ctDNA) and first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) harboring RAS mutation

Author

Sunakawa, Y., primary, Usher, J., additional, Satake, H., additional, Jaimes, Y., additional, Miyamoto, Y., additional, Nakamura, M., additional, Kataoka, M., additional, Shiozawa, M., additional, Takagane, A., additional, Terazawa, T., additional, Watanabe, T., additional, Ishigure, K., additional, Tanaka, C., additional, Sekikawa, T., additional, Takeuchi, M., additional, Fujii, M., additional, Danenberg, K., additional, Danenberg, P.V., additional, Lenz, H.-J., additional, and Ichikawa, W., additional

Published
2018
Full Text
View/download PDF

73. The feasibility study of short hydration with oral rehydration therapy in chemotherapy with cisplatin plus gemcitabine for biliary tract cancer (KHBO-1302)

Author

Ioka, T., primary, Sakai, D., additional, Wada, H., additional, Eguchi, H., additional, Yanagihara, K., additional, Satake, H., additional, Shimizu, J., additional, Kanai, M., additional, Hashimoto, K., additional, Ajiki, T., additional, Nakamura, M., additional, Takeda, Y., additional, Yoshimura, K., additional, Hatano, E., additional, and Nagano, H., additional

Published
2018
Full Text
View/download PDF

74. Multicenter phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study) - Trial in progress

Author

Kato, T., primary, Satake, H., additional, Oba, K., additional, Kagawa, Y., additional, Yasui, H., additional, Nakamura, M., additional, Watanabe, T., additional, Matsumoto, T., additional, Hirata, K., additional, Muro, K., additional, Komatsu, Y., additional, Yoshino, T., additional, Yamazaki, K., additional, Mishima, H., additional, Kotaka, M., additional, Tsuji, A., additional, Kakeji, Y., additional, Oki, E., additional, Nagata, N., additional, and Sakamoto, J., additional

Published
2018
Full Text
View/download PDF

77. SAPPHIRE: A randomized phase II study of oxaliplatin discontinuation after 6 cycles of mFOLFOX6 + panitumumab therapy in patients with colorectal cancer: Final analysis of efficacy and safety results

Author

Takahashi, M., primary, Munemoto, Y., additional, Nakamura, M., additional, Kotaka, M., additional, Kuroda, H., additional, Kato, T., additional, Minagawa, N., additional, Noura, S., additional, Fukunaga, M., additional, Kuramochi, H., additional, Touyama, T., additional, Takahashi, T., additional, Akagi, Y., additional, Satake, H., additional, Kurosawa, S., additional, Miura, T., additional, Mishima, H., additional, Sakamoto, J., additional, Oba, K., additional, and Nagata, N., additional

Published
2018
Full Text
View/download PDF

79. A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study

Author

Yamazaki, K., primary, Yasui, H., additional, Yamaguchi, K., additional, Kagawa, Y., additional, Kuboki, Y., additional, Yoshino, T., additional, Gamoh, M., additional, Komatsu, Y., additional, Satake, H., additional, Goto, M., additional, Tanioka, H., additional, Oki, E., additional, Kotaka, M., additional, Makiyama, A., additional, Denda, T., additional, Soeda, J., additional, Shibya, K., additional, Iwata, M., additional, Oba, K., additional, and Kato, T., additional

Published
2018
Full Text
View/download PDF

80. Optimum structure of deposited ultrathin silicon oxynitride film to minimize leakage current.

Author

Muraoka, K., Kurihara, K., Yasuda, N., and Satake, H.

Subjects
THIN films, SILICON compounds, STRAY currents
Abstract

The role of oxygen inside deposited silicon oxynitride (SION) films with respect to leakage current was investigated. We controlled the composition of bulk SiON film in accordance with the alloy model (Si[sub 3]N[sub 4])[sub x](SiO[sub 2])[sub 1-x] regarding the ultrathin composite SiON structure and stacked SiON/SiO[sub 2] structure and measured electrical properties of these SiON films. Furthermore, we studied the conduction mechanisms of the leakage current for these films by using a direct tunneling (DT) current simulation with Wentzel-Kramers-Brillouin approximation, taking the dielectric constant, band profile, and effective mass into consideration. From these experiments and simulations, it was found that the leakage current of composite structure is lower than that of the stacked structure, even if those structures have the same alloy ratio x. Furthermore, we found the optimum film composition to minimize the DT current. The optimum structure was determined by the balance between the decrease in the electron DT current and the increase in the hole DT current due to the physical thickness and the valence-band barrier height. [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

81. EARLY PREDICTION OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY FOR LOCALLY ADVANCED BREAST CANCER USING MRI

Author

Kawamura, M., Satake, H., Ishigaki, S., Nishio, A., Sawaki, M., and Shinji Naganawa

Subjects
Adult, Original Paper, Receptor, ErbB-2, Breast Neoplasms, Middle Aged, Neoadjuvant chemotherapy, Magnetic Resonance Imaging, Breast cancer, Chemotherapy, Adjuvant, Response prediction, Humans, Female, MRI, Aged
Abstract

Neoadjuvant chemotherapy (NAC) is the favored treatment of choice among locally advanced breast cancer patients because it significantly increases the possibility of breast-conserving surgery. However, for non-responders, an early prediction of response to NAC is essential. The purpose of this study was to determine whether an early prediction of response to NAC is possible using MRI. Eleven breast cancer patients (12 lesions) scheduled to receive NAC were recruited for this study. The patients were examined by MRI prior to and after the first and fourth courses of anthracycline-containing chemotherapy and after subsequent taxane-containing chemotherapy. Lesions were divided into 2 types (mass type and non-mass type) based on contrast MRI prior to chemotherapy. Among 8 mass types, 6 were responders (R) and 2 were non-responders (NR). R cases showed either an increased apparent diffusion coefficient (ADC) or volume reduction after the first course of NAC, whereas NR cases showed neither (p

Published
2011

84. Dynamic changes in levels of gene mutations using circulating tumor DNA (ctDNA) and efficacy of 1st-line modified (m)-FOLFOXIRI plus bevacizumab (bev) for metastatic colorectal cancer (mCRC) harboring RAS mutation (mt) (JACCRO CC-11)

Author

Sunakawa, Y., primary, Sekikawa, T., additional, Usher, J., additional, Satake, H., additional, Jaimes, Y., additional, Miyamoto, Y., additional, Nakamura, M., additional, Nakayama, H., additional, Kazama, K., additional, Takagane, A., additional, Makiyama, A., additional, Kobayashi, K., additional, Kubota, Y., additional, Mori, M., additional, Kotaka, M., additional, Takeuchi, M., additional, Fujii, M., additional, Danenberg, K., additional, Lenz, H-J., additional, and Ichikawa, W., additional

Published
2017
Full Text
View/download PDF

85. Predictive value of primary tumor location: Results from randomized phase II study of panitumumab + irinotecan versus cetuximab + irinotecan in patients with KRAS exon2 wild-type metastatic colorectal cancer (WJOG6510G)

Author

Tamura, T., primary, Sakai, D., additional, Sugimoto, N., additional, Tokunaga, S., additional, Tsuji, A., additional, Ishida, H., additional, Otsu, S., additional, Moriwaki, T., additional, Satake, H., additional, Uchino, K., additional, Matsumoto, S., additional, Baba, E., additional, Sato, M., additional, Taniguchi, H., additional, Kishimoto, J., additional, Boku, N., additional, Hyodo, I., additional, and Muro, K., additional

Published
2017
Full Text
View/download PDF

92. Characterization of a cDNA encoding a novel avian hypothalamic neuropeptide exerting an inhibitory effect on gonadotropin release

Author

Satake, H, Hisada, M, Kawada, T, Minakata, H, Ukena, K, and Tsutsui, K

Subjects
Brain Chemistry, Male, endocrine system, DNA, Complementary, Hypothalamic Hormones, Base Sequence, Transcription, Genetic, Protein Conformation, Reverse Transcriptase Polymerase Chain Reaction, Molecular Sequence Data, Coturnix, Cell Biology, Biochemistry, Avian Proteins, Molecular Weight, Pituitary Gland, Anterior, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Animals, Amino Acid Sequence, Diencephalon, Protein Precursors, Molecular Biology, Gonadotropins, Research Article
Abstract

We previously isolated a novel dodecapeptide containing a C-terminal -Arg-Phe-NH2 sequence, SIKPSAYLPLRF-NH2 (RFamide peptide), from the quail brain. This quail RFamide peptide was shown to decrease gonadotropin release from the cultured anterior pituitary and to be located at least in the quail hypothalamo-hypophysial system. We therefore designated this RFamide peptide gonadotropin inhibitory hormone (GnIH). In the present study we characterized the GnIH cDNA from the quail brain by a combination of 3′ and 5′ rapid amplification of cDNA ends (‘RACE’). The deduced GnIH precursor consisted of 173 amino acid residues, encoding one GnIH and two putative gene-related peptide (GnIH-RP-1 and GnIH-RP-2) sequences that included -LPXRF (X = L or Q) at their C-termini. All these peptide sequences were flanked by a glycine C-terminal amidation signal and a single basic amino acid on each end as an endoproteolytic site. Southern blotting analysis of reverse-transcriptase-mediated PCR products demonstrated a specific expression of the gene encoding GnIH in the diencephalon including the hypothalamus. Furthermore, mass spectrometric analyses detected the mass numbers for matured GnIH and GnIH-RP-2, revealing that both peptides are produced from the precursor in the diencephalon as an endogenous ligand. Taken together, these results lead to the conclusion that GnIH is a hypothalamic factor responsible for the negative regulation of gonadotropin secretion. Furthermore, the presence of a novel RFamide peptide family containing a C-terminal -LPXRF-NH2 sequence has been revealed.

Published
2001

93. Chemotherapy in cancer patients undergoing hemodialysis: A multicenter study

Author

Funakoshi, T., primary, Horimatsu, T., additional, Nakamura, M., additional, Suyama, K., additional, Mizukami, T., additional, Arita, S., additional, Ozaki, Y., additional, Yasui, H., additional, Satake, H., additional, Toyoda, M., additional, Yazumi, S., additional, Kirishima, T., additional, Nozaki, A., additional, Yoshioka, A., additional, Matsubara, T., additional, Yanagita, M., additional, Fukuhara, S., additional, and Muto, M., additional

Published
2016
Full Text
View/download PDF

94. Phase II study to evaluate the efficacy of regorafenib in metastatic colorectal cancer patients by the assessment using FDG-PET/CT (JACCRO CC-12) metastatic colorectal cancer (JACCRO CC-12)

Author

Satake, H., primary, Nakamura, M., additional, Tsuji, A., additional, Sagawa, T., additional, Tamura, F., additional, Hatachi, Y., additional, Oguchi, K., additional, Takagane, A., additional, Kaji, T., additional, Sekikawa, T., additional, Furukawa, M., additional, Kochi, M., additional, Ichikawa, W., additional, Takeuchi, M., additional, Fujii, M., additional, and Nakajima, T., additional

Published
2016
Full Text
View/download PDF

95. Phase II study of third-line cetuximab rechallenge in patients with metastatic wild-type K-RAS colorectal cancer who achieved a clinical benefit in response to first-line cetuximab plus chemotherapy (JACCRO CC-08)

Author

Tsuji, A., primary, Eto, T., additional, Masuishi, T., additional, Satake, H., additional, Segawa, Y., additional, Tanioka, H., additional, Hara, H., additional, Kotaka, M., additional, Sagawa, T., additional, Watanabe, T., additional, Nakamura, M., additional, Takahashi, T., additional, Negoro, Y., additional, Manaka, D., additional, Fujita, H., additional, Suto, T., additional, Ichikawa, W., additional, Fujii, M., additional, Takeuchi, M., additional, and Nakajima, T., additional

Published
2016
Full Text
View/download PDF

96. Updated report: A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402)

Author

Yuki, S., primary, Komatsu, Y., additional, Satake, H., additional, Miyamoto, Y., additional, Tanioka, H., additional, Tsuji, A., additional, Asayama, M., additional, Shiraishi, T., additional, Kotaka, M., additional, Makiyama, A., additional, Kashiwada, T., additional, Takeuchi, N., additional, Shimokawa, M., additional, Saeki, H., additional, Oki, E., additional, Emi, Y., additional, Baba, H., additional, and Maehara, Y., additional

Published
2016
Full Text
View/download PDF

99. P-059 Phase I trial of FOLFOXIRI in combination with Panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer (JACCRO CC-14)

Author

Tsuji, A., primary, Nakamura, M., additional, Ogawa, M., additional, Satake, H., additional, Kotake, T., additional, Hatachi, Y., additional, Takagane, A., additional, Okita, Y., additional, Nakamura, K., additional, Onikubo, T., additional, Takeuchi, M., additional, Fujii, M., additional, and Nakajima, T., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results